Low blood pressure and the effect of SGLT2 inhibitors in heart failure with reduced ejection fraction: data from the China Cardiovascular Association Database-Heart Failure Center Registry
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have become a cornerstone of treatment in heart failure with reduced ejection fraction (HFrEF) management, but data on their use in HFrEF with systolic blood pressure (SBP) lower than 100 mmHg remain limited. To assess the real-world efficacy of SGLT2i in...